We also show that a serum CEA level of less than 10 ng/ml was a predictor of favorable outcomes in advanced lung adenocarcinoma patients with EGFR-sensitive mutations (exon 19 deletion and L858R). Here, CEACAM5 is linked to lung adenocarcinoma.